DDP-IV inhibitors improve insulin sensitivity and hepatic steatosis in animal models of diet-induced obesity with some evidence of improved liver inflammation [99] and may also limit progression to fibrosis in animal models of liver injury [100]. Here, INS is linked to Hepatic steatosis.